Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Operating Expenses (2022 - 2025)

Summit Therapeutics (SMMT) has disclosed Operating Expenses for 4 consecutive years, with $224.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 242.8% year-over-year to $224.9 million, compared with a TTM value of $1.1 billion through Dec 2025, up 384.26%, and an annual FY2025 reading of $1.1 billion, up 384.26% over the prior year.
  • Operating Expenses was $224.9 million for Q4 2025 at Summit Therapeutics, down from $234.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $568.4 million in Q2 2025 and bottomed at $5.4 million in Q4 2022.
  • Average Operating Expenses over 4 years is $139.9 million, with a median of $59.0 million recorded in 2024.
  • The sharpest move saw Operating Expenses tumbled 92.12% in 2024, then soared 853.48% in 2025.
  • Year by year, Operating Expenses stood at $5.4 million in 2022, then soared by 557.04% to $35.4 million in 2023, then surged by 85.41% to $65.6 million in 2024, then surged by 242.8% to $224.9 million in 2025.
  • Business Quant data shows Operating Expenses for SMMT at $224.9 million in Q4 2025, $234.2 million in Q3 2025, and $568.4 million in Q2 2025.